Risk factors for developing eosinophilia myalgia syndrome among L-tryptophan users in New York.
Using a case-control study design, patients with eosinophilia myalgia syndrome (EMS) who had used L-tryptophan (LT) were compared with LT users who did not develop EMS. Of the 113 case patients and 95 controls who had used a retail brand that could be traced to a bulk LT producer, all (100%) case-patients and 69 (73%) controls used LT brands that were traced to Showa Denko K.K. (lower 95% CL = 10.0). Among the users of LT produced by Showa Denko K.K., the risk of EMS was greater for persons who used LT produced after December 1, 1988 (OR = 25.8, [95% CL = 7.1, 101.4]). The risk of developing EMS increased with increased dosage of LT, increased age, and use of LT as a sleeping aid. These epidemiologic data support the hypothesis that the etiologic agent in EMS is a contaminant introduced into LT products during production.
Division of Field Epidemiology, Centers for Disease Control, Albany, NY.
E E
EE
Back
K J
KJ
Henning
L R
LR
Kallenbach
K A
KA
Brix
R A
RA
Gunn
J M
JM
Melius
D000293:Adolescent; D000328:Adult; D016022:Case-Control Studies; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004345:Drug Industry; D016603:Eosinophilia-Myalgia Syndrome / Q000139:chemically induced*; D005260:Female; D006801:Humans; D008297:Male; D009518:New York; D012044:Regression Analysis; D012307:Risk Factors; D014364:Tryptophan / Q000009:adverse effects*
D014364:Tryptophan